Market Closed -
OTC Markets
01:49:06 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
0.0007
USD
|
0.00%
|
|
-12.50%
|
+16.67%
|
Fiscal Period: September |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
59.74
|
149.3
|
7.665
|
10.48
|
4.423
|
0.4014
|
Enterprise Value (EV)
1 |
60.52
|
149.4
|
8.367
|
10.73
|
4.753
|
0.773
|
P/E ratio
|
-67
x
|
-193
x
|
-2.69
x
|
-1.78
x
|
-4.61
x
|
-0.57
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
133,896,598
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
257,842,228
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-106
x
|
-164
x
|
13.6
x
|
-10.5
x
|
-27.3
x
|
4.39
x
|
FCF Yield
|
-0.94%
|
-0.61%
|
7.33%
|
-9.5%
|
-3.67%
|
22.8%
|
Price to Book
|
-150
x
|
-182
x
|
-2.65
x
|
-6.37
x
|
-2.49
x
|
-0.19
x
|
Nbr of stocks (in thousands)
|
20,600
|
74,672
|
95,806
|
381,171
|
442,261
|
573,461
|
Reference price
2 |
2.900
|
2.000
|
0.0800
|
0.0275
|
0.0100
|
0.000700
|
Announcement Date
|
3/20/19
|
12/27/19
|
1/8/21
|
12/29/21
|
1/17/23
|
1/9/24
|
Fiscal Period: September |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
-
|
-
|
-
|
-
|
0.002998
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-0.6698
|
-0.7737
|
-0.4857
|
-0.7527
|
-1.07
|
-0.474
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-15,810.84%
|
Earnings before Tax (EBT)
1 |
-0.7421
|
-0.7688
|
-2.483
|
-4.532
|
-0.8755
|
-0.5688
|
Net income
1 |
-1.074
|
-0.7675
|
-2.438
|
-4.532
|
-0.8755
|
-0.5688
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-18,971.81%
|
EPS
2 |
-0.0433
|
-0.0104
|
-0.0297
|
-0.0154
|
-0.002168
|
-0.001219
|
Free Cash Flow
1 |
-0.5687
|
-0.9135
|
0.6137
|
-1.019
|
-0.1743
|
0.1762
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
5,878.02%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/20/19
|
12/27/19
|
1/8/21
|
12/29/21
|
1/17/23
|
1/9/24
|
Fiscal Period: September |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
0.78
|
0.01
|
0.7
|
0.24
|
0.33
|
0.37
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-0.57
|
-0.91
|
0.61
|
-1.02
|
-0.17
|
0.18
|
ROE (net income / shareholders' equity)
|
39.2%
|
69.2%
|
132%
|
196%
|
49.8%
|
28.4%
|
ROA (Net income/ Total Assets)
|
-90.5%
|
-89.6%
|
-67.7%
|
-147%
|
-230%
|
-179%
|
Assets
1 |
1.186
|
0.8569
|
3.6
|
3.079
|
0.3811
|
0.3173
|
Book Value Per Share
2 |
-0.0200
|
-0.0100
|
-0.0300
|
-0
|
-0
|
-0
|
Cash Flow per Share
2 |
0
|
0
|
0
|
0
|
0
|
0
|
Capex
1 |
0.25
|
0.2
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/20/19
|
12/27/19
|
1/8/21
|
12/29/21
|
1/17/23
|
1/9/24
|
|
1st Jan change
|
Capi.
|
---|
| +16.67% | 465K | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|